Lin Chun-Yu, Huang Shu-Hua, Chen Tun-Chieh, Lu Po-Liang, Lin Wei-Ru, Chen Yen-Hsu
Division of Infectious Disease, Department of Internal Medicine, Kaohsiung Medical University Chun-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
J Microbiol Immunol Infect. 2008 Aug;41(4):325-31.
Increasing rates of fluoroquinolone resistance among Escherichia coli have been reported in Taiwan and worldwide. We aimed to identify the risk factors of ciprofloxacin resistance in urinary E. coli isolates.
Patients with positive urine culture result for E. coli and resistance to ciprofloxacin between September 1, 1999 and December 31, 1999 were prospectively identified as cases, and compared with ciprofloxacin-susceptible E. coli isolates (controls).
control ratio was 1:2. Data were collected with standardized case record forms.
Sixty one cases and 122 controls were compared. Multivariate analysis indicated that urinary tract catheterization (odds ratio [OR] = 2.631, 95% confidence interval [CI] = 1.058-6.544; p=0.037) and prior exposure to quinolones (OR = 13.072, 95% CI = 3.367-50.75; p<0.001) were independent risk factors for ciprofloxacin resistance in urinary E. coli isolates. Compared with ciprofloxacin-susceptible E. coli isolates, ciprofloxacin-resistant E. coli isolates from urine specimens had a significantly higher rate of resistance to all other tested antimicrobial agents, except amikacin and imipenem.
In patients with urinary tract infection, urinary catheterization and prior quinolone exposure are associated with a high risk of ciprofloxacin-resistant E. coli which may cause treatment failure.
台湾及全球范围内均有报道称大肠杆菌对氟喹诺酮类药物的耐药率不断上升。我们旨在确定尿源性大肠杆菌分离株对环丙沙星耐药的危险因素。
前瞻性地将1999年9月1日至1999年12月31日期间尿培养结果为大肠杆菌且对环丙沙星耐药的患者确定为病例,并与对环丙沙星敏感的大肠杆菌分离株(对照)进行比较。
病例与对照比例为1:2。通过标准化病例记录表收集数据。
对61例病例和122例对照进行了比较。多变量分析表明,导尿(比值比[OR]=2.631,95%置信区间[CI]=1.058 - 6.544;p = 0.037)和先前接触喹诺酮类药物(OR = 13.072,95% CI = 3.367 - 50.75;p < 0.001)是尿源性大肠杆菌分离株对环丙沙星耐药的独立危险因素。与对环丙沙星敏感的大肠杆菌分离株相比,尿标本中对环丙沙星耐药的大肠杆菌分离株对所有其他测试抗菌药物的耐药率显著更高,但阿米卡星和亚胺培南除外。
在尿路感染患者中,导尿和先前接触喹诺酮类药物与耐环丙沙星大肠杆菌的高风险相关,这可能导致治疗失败。